Patents Examined by Susan Ungar
-
Patent number: 7348412Abstract: The invention relates to a monoclonal antibody or antigen binding fragment thereof having binding specificity for ouabain, wherein the antibody or antigen binding fragment does not crossreact with digoxin. Preferably the anti-ouabain monoclonal antibody can bind ouabain with an affinity of at least about 10?7M, preferably 10?8M, and more preferably 10?9M. The invention also relates to diagnostic and therapeutic uses of the monoclonal antibodies described herein.Type: GrantFiled: October 5, 1999Date of Patent: March 25, 2008Assignee: The General Hospital CorporationInventors: Behnaz Parhami-Seren, Michael N. Margolies, Garner T. Haupert, Jr.
-
Patent number: 7344713Abstract: A method for the decrease of fat absorption in a mammal, wherein the animal is orally fed an antibody produced against lipase, an enzyme which is required for fat absorption.Type: GrantFiled: July 7, 1997Date of Patent: March 18, 2008Inventor: Julio L. Pimentel
-
Patent number: 7344829Abstract: Methods for determining the effectiveness of anticancer agents by determining and comparing growth factor receptor phosphorylation levels in samples obtained by non-invasive procedures before and after anticancer treatments are provided. The invention also provides methods for detecting growth factor receptor phosphorylation in hair follicles and other tissues obtained by non-invasive means.Type: GrantFiled: November 2, 2001Date of Patent: March 18, 2008Assignee: Board of Regents, the University of Texas SystemInventors: Isaiah J. Fidler, Corazon D. Bucana
-
Patent number: 7341869Abstract: The present invention provides an isolated population of cells containing an expressible nucleic acid encoding proinsulin containing a proinsulin cleavage site and a glucose-regulated expressible nucleic acid encoding a protease capable of cleaving the proinsulin cleavage site to produce insulin. The invention also provides an isolated population of cells which further express a hexosamine synthetic pathway enzyme. The invention additionally provides vectors containing an expressible nucleic acid encoding proinsulin containing a proinsulin cleavage site and a glucose-regulated expressible nucleic acid encoding a protease capable of cleaving the proinsulin cleavage site to produce insulin. The invention further provides a method of treating or preventing diabetes by implanting into an individual cells coexpressing proinsulin containing a proinsulin cleavage site and a glucose-regulated protease capable of cleaving the proinsulin cleavage site to produce insulin.Type: GrantFiled: December 23, 2002Date of Patent: March 11, 2008Assignee: The University of WashingtonInventors: William R. A. Osborne, Nagarajan Ramesh
-
Patent number: 7342100Abstract: Methods and agents that interfere with Hpr6 function in non-sarcoma tumor cells are disclosed. Anti-Hpr6 agents are used to enhance the killing effect of anti-cancer agents in non-sarcoma tumor cells and to teat non-sarcoma tumors.Type: GrantFiled: June 4, 2004Date of Patent: March 11, 2008Assignee: University of Kentucky Research FoundationInventor: Rolf Joseph Craven
-
Patent number: 7338767Abstract: Microphthalmia (Mi) while present in melanocytes, a cells and osteoclast, is not normally present in other cells. We have found that Mi is present in the nucleus of melanoma cells. Melanoma can be diagnosed by contacting a malignant cell with a probe for Mi. If the probe identifies Mi in the nucleus of the cell, the cell is a melanoma.Type: GrantFiled: January 13, 1999Date of Patent: March 4, 2008Assignee: Dana-Farber Cancer Institute, Inc.Inventor: David E. Fisher
-
Patent number: 7338766Abstract: The present invention relates to cupredoxin and cytochrome and their use, separately or together, to inhibit the spread of parasitemia in mammalian red blood cells and other tissues infected by the malaria parasite, and in particular the parasitemia of human red blood cells by P. falciparum. The invention provides isolated peptides that are variants, derivatives or structural equivalents of cupredoxins or cytochrome c, and compositions comprising cupredoxins and/or cytochrome c, or variants, derivatives or structural equivalents thereof, that are useful for treating or preventing malaria infection in mammals. Further, the invention provides methods to treat mammalian patients to prevent or inhibit the growth of malarial infection in mammals. The invention also provides methods to prevent the growth of malaria infection in insect vectors.Type: GrantFiled: May 19, 2006Date of Patent: March 4, 2008Assignee: The Board of Trustees of the University of IllinoisInventors: Ananda Chakrabarty, Tapas Das Gupta, Tohru Yamada, Anita Chaudhari, Arsenio Fialho, Chang Soo Hong
-
Patent number: 7335749Abstract: The invention provides isolated nucleic acid and amino acid sequences of novel human tumor suppressors, antibodies to such tumor suppressors, methods of detecting such nucleic acids and proteins, methods of screening for modulators of tumor suppressors, and methods of diagnosing and treating tumors with such nucleic acids and proteins.Type: GrantFiled: February 9, 2001Date of Patent: February 26, 2008Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Curtis C. Harris, Makoto Nagashima
-
Patent number: 7329738Abstract: This invention provides novel methods, reagents, and kits that are useful for detecting B. anthracis. The methods are based on the discovery of binding agents, including recombinant polyclonal antibodies, which bind to the surface array protein of B. anthracis.Type: GrantFiled: July 12, 2004Date of Patent: February 12, 2008Assignee: Biosite IncorporatedInventors: Bruce Andrew Lee, Becky Mar Flores, Gunars Edwin Valkirs
-
Patent number: 7323173Abstract: Mammastatin has an approximate molecular weight of 44 kDa in its inactive, non-phosphorylated form. Normal mammary cells express functional phosphorylated forms having approximate molecular weights of 53 kDa and 49 kDa. Metastatic mammary cells either do not express Mammastatin at all, or do not express the 53 kDa or 49 kDa, phosphorylated forms. Mammary cancer cells are inhibited in their growth by the administration of phosphorylated Mammastatin.Type: GrantFiled: July 9, 2002Date of Patent: January 29, 2008Assignee: The Regents of the University of MichiganInventor: Paul R. Ervin, Jr.
-
Patent number: 7319011Abstract: Follicular thyroid adenoma (FTA) is distinguished from follicular thyroid carcinoma (FTC) by comparing amount of an expression product of at least one gene selected from the group consisting of DDIT3, ARG2, ITM1, C1orf24, TARSH, and ACO1 in a test follicular thyroid specimen to a normal control thyroid specimen. The test follicular thyroid specimen is identified as FTA if the amount of expression product of TARSH is equal to or greater in the test follicular thyroid specimen than in the normal control thyroid specimen. The test follicular thyroid specimen is identified as FTC if the amount of expression product of DDIT3, ARG2, ITM1, C1orf24, or ACO1 is greater in the test follicular thyroid specimen than in the normal control thyroid specimen.Type: GrantFiled: April 7, 2005Date of Patent: January 15, 2008Assignee: Duke UniversityInventors: Gregory J. Riggins, Janete Cerruti
-
Patent number: 7319010Abstract: The present invention relates to compositions and methods for cancer therapies and diagnostics, including but not limited to, cancer markers. In particular, the present invention provides tumor antigens associated with specific cancers and diagnostic assays for the detection of such antigens and associated autoantibodies as indicative of the presence of specific cancers. The present invention further provides cancer immunotherapy utilizing the tumor antigens of the present invention.Type: GrantFiled: May 12, 2004Date of Patent: January 15, 2008Assignee: The Regents of the University of MichiganInventors: Myeong Nam, Juan Madoz-Gurpide, Hong Wang, David E. Misek, Samir M. Hanash
-
Patent number: 7316906Abstract: The subject invention discloses a method for determining the prognosis and probable clinical course of a subject diagnosed with B-CLL. Specifically, the invention involves comparing CD38 expression in a biological sample from the subject containing B-CLL cells to a baseline level of CD38 expression, wherein an elevated level of CD38 expression in relation to the baseline level of CD38 expression may indicate poor prognosis or aggressive course of disease in the subject. Also disclosed is a method for determining whether the Ig V genes of the B-CLL cells of a B-CLL patient are mutated, comprising comparing CD38 expression in a biological sample from the subject containing B-CLL cells to a baseline level of CD38 expression, wherein a lower level of CD38 expression in relation to the baseline level indicates IG V gene mutation.Type: GrantFiled: August 2, 2002Date of Patent: January 8, 2008Assignee: The Feinstein Institute for Medical ResearchInventors: Nicholas Chiorazzi, Rajendra N. Damle, Tarun Wasil
-
Patent number: 7314721Abstract: Cancer associated antigens have been identified by autologous antibody screening of libraries of nucleic acids expressed in small cell lung cancer cells using antisera from cancer patients. The invention relates to nucleic acids and encoded polypeptides which are cancer associated antigens expressed in patients afflicted with small cell lung cancer. The invention provides, among other things, isolated nucleic acid molecules, expression vectors containing those molecules and host cells transfected with those molecules. The invention also provides isolated proteins and peptides, antibodies to those proteins and peptides and cytotoxic T lymphocytes which recognize the proteins and peptides. Fragments of the foregoing including functional fragments and variants also are provided. Kits containing the foregoing molecules additionally are provided.Type: GrantFiled: January 20, 2004Date of Patent: January 1, 2008Assignees: Ludwig Institute for Cancer Research, Memorial Sloan-Kettering Cancer Center, New York Hospital-Cornell Medical CenterInventors: Ali O. Gure, Elisabeth Stockert, Matthew J. Scanlan, Dirk Jager, Lloyd J. Old, Yao-Tseng Chen
-
Patent number: 7314709Abstract: A method of detecting an activity of a COX-2 enzyme in a subject that includes obtaining a sample of the subject; detecting an amino acid eicosanoid metabolite in the sample, wherein the presence of the amino acid eicosanoid metabolite indicates the activity of the COX-2 enzyme of the subject. Preferably the amino acid eicosanoid metabolite is a PGH2-Gly or HETE-Gly metabolite. The metabolite may be detected based on metabolism of a COX-2-selective substrate. Preferably, the substrate is a lipoamino acid. More preferably, the lipoamino acid is selected from NAGly, N-arachidonyl-alanine, and ?-arachidonyl aminobutuyic acid.Type: GrantFiled: August 6, 2002Date of Patent: January 1, 2008Assignee: Vanderbilt UniversityInventors: Lawrence J. Marnett, Jeffery J. Prusakiewicz, Kevin R. Kozak, Philip J. Kingsley
-
Patent number: 7311911Abstract: The present invention provides methods for reducing or inhibiting angiogenesis in a tissue, by contacting ?5?1 integrin in the tissue with an agent that interferes with the specific binding of ?5?1 integrin to a ligand expressed in the tissue; and methods of identifying angiogenesis in a tissue, by contacting the tissue with an agent that specifically binds ?5?1 integrin, and detecting specific binding of the agent to ?5?1 integrin associated with a blood vessel in the tissue. Also provided are methods of diagnosing a pathological condition characterized by angiogenesis in a tissue in an individual; methods of reducing or inhibiting angio genesis in a tissue in an individual; and methods of reducing the severity of a pathological condition associated with angiogenesis in an individual, by administering to the individual an agent that interferes with specific binding of ?5?1 integrin to a ligand in a tissue associated with the pathological condition.Type: GrantFiled: October 14, 2003Date of Patent: December 25, 2007Assignee: The Regents of the University of CaliforniaInventor: Judith A. Varner
-
Patent number: 7306806Abstract: In this application is the expression and purification of a recombinant Plasmodium falciparum (3D7) MSP-142. The method of the present invention produces a highly purified protein which retains folding and disulfide bridging of the native molecule. The recombinant MSP-142 is useful as a diagnostic reagent, for use in antibody production, and as a vaccine.Type: GrantFiled: January 25, 2002Date of Patent: December 11, 2007Assignee: United States of America as represented by the Secretary of the ArmyInventors: Jeffrey A. Lyon, Evelina Angov, Joe D. Cohen, Gerald Voss
-
Patent number: 7297341Abstract: The present invention provides purified and isolated polynucleotide molecules that encode Chlamydia polypeptides which can be used in methods to prevent, treat, and diagnose Chlamydia infection. In one form of the invention, the polynucleotide molecules are selected from DNA that encode polypeptides CPN100686 RY 54 (SEQ ID Nos: 1 and 14), CPN100696 RY-55 (SEQ ID Nos: 2 and 15), CPN100709 RY-57 (SEQ ID Nos: 3 and 16), CPN100710 RY-58 (SEQ ID Nos: 4 and 17), CPN100711 RY-59 (SEQ ID Nos: 5 and 18), CPN100877 RY-61 (SEQ ID Nos: 6 and 19), CPN100325 RY-62 (SEQ ID Nos: 7 and 20), CPN100368 RY-63 (SEQ ID Nos: 8 and 21), CPN100624 RY-64 (SEQ ID Nos:9 and 22), CPN100633 RY-65 (SEQ ID Nos:10 and 23), CPN100985 RY-66 (SEQ ID Nos:11 and 24), CPN100987 RY-67 (SEQ ID Nos:12 and 25) and CPN100988 RY-68 (SEQ ID Nos:13 and 26).Type: GrantFiled: December 23, 1999Date of Patent: November 20, 2007Assignee: Sanofi Pasteur LimitedInventors: Andrew D. Murdin, Raymond P. Oomen, Joe Wang
-
Patent number: 7294468Abstract: The present invention is directed to a method for determining the responsiveness of cancer to an epidermal growth factor receptor (EGFR) treatment. In a preferred embodiment, the presence of at least one variance in the kinase domain of the erbB1 gene confers sensitivity to the tyrosine kinase inhibitor gefitinib. Thus, a diagnostic assay for these mutations will allow for the administration of gefitinib, erlotinib and other tyrosine kinase inhibitors to those patients most likely to respond to the drug.Type: GrantFiled: December 5, 2005Date of Patent: November 13, 2007Assignees: The General Hospital Corporation, Dana-Farber Cancer Institute, Inc.Inventors: Daphne Winifred Bell, Daniel A. Haber, Pasi Antero Janne, Bruce E. Johnson, Thomas J. Lynch, Matthew Meyerson, Juan Guillermo Paez, William R. Sellers, Jeffrey E. Settleman, Raffaella Sordella
-
Patent number: 7291722Abstract: The invention provides BASB203 polypeptides and polynucleotides encoding BASB203 polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are diagnostic, prophylactic and therapeutic uses.Type: GrantFiled: October 5, 2001Date of Patent: November 6, 2007Assignee: GlaxoSmithKline Biologicals, S.A.Inventor: Joelle Thonnard